MR. LAWRENCE STEINMAN, MD
Neurology at Pasteur Dr, Palo Alto, CA
License number
California G27574
Category
Neurology
Type
Neurology
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 498-5710
Professional information
Treatment Of Demyelinating Autoimmune Disease With Ordered Peptides
US Patent:
7070780, Jul 4, 2006
Filed:
May 20, 2002
Appl. No.:
10/152654
Inventors:
Lawrence Steinman - Palo Alto CA, US
Pedro Jose Ruiz - Redwood City CA, US
Pedro Jose Ruiz - Redwood City CA, US
Assignee:
Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39/00, A61K 38/04, A61K 38/08, A61K 38/17
US Classification:
4241841, 4241851, 530325, 530326, 530327, 530328
Abstract:
Compositions and methods are provided for the treatment of demyelinating autoimmune disease. Therapeutic doses are administered of an ordered peptide comprising a repeated motif {SEQ ID NO: 1} [EYYK], where n is from 2 to 6. Some specific peptides of interest include those having the sequence {SEQ ID NO:4} EYYKEYYKEYYK. The peptide may consist only of the ordered repeats, or may be extended at either termini by the addition of other amino acid residues. For therapy, the peptides may be administered topically or parenterally, e. g. by injection at a particular site, including subcutaneously, intraperitoneally, intravascularly, or the like or transdermally, as by electrotransport. In a preferred embodiment, subcutaneous injection is used to deliver the peptide. The subject methods are used for prophylactic or therapeutic purposes. The compositions of the invention may also contain other therapeutically active agents, e. g.
Trp/His Exchange And Kynurenine Induced Trp Transport
US Patent:
7935494, May 3, 2011
Filed:
Feb 29, 2008
Appl. No.:
12/040524
Inventors:
Thijs Kaper - Palo Alto CA, US
Michael Platten - Dossenheim, DE
Lawrence Steinman - Stanford CA, US
Wolf Frommer - Stanford CA, US
Michael Platten - Dossenheim, DE
Lawrence Steinman - Stanford CA, US
Wolf Frommer - Stanford CA, US
Assignee:
Carnegie Institution of Washington - Washington DC
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
G01N 33/53
US Classification:
435 72
Abstract:
The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp/kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression.
Therapeutic And Diagnostic Uses Of Antibody Specificity Profiles
US Patent:
2010033, Dec 30, 2010
Filed:
Aug 30, 2010
Appl. No.:
12/871765
Inventors:
William H. Robinson - Menlo Park CA, US
David L. Hirschberg - Menlo Park CA, US
Lawrence Steinman - Palo Alto CA, US
Pedro Jose Ruiz - Menlo Park CA, US
Paul J. Utz - Stanford CA, US
Hideki Garren - Palo Alto CA, US
David L. Hirschberg - Menlo Park CA, US
Lawrence Steinman - Palo Alto CA, US
Pedro Jose Ruiz - Menlo Park CA, US
Paul J. Utz - Stanford CA, US
Hideki Garren - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39/00, C40B 30/04, C40B 40/10, A61P 3/10
US Classification:
4241841, 506 9, 506 18
Abstract:
This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.
Cryptic Glycan Markers And Applications Thereof
US Patent:
2010017, Jul 15, 2010
Filed:
Jan 12, 2010
Appl. No.:
12/686102
Inventors:
Denong Wang - Palo Alto CA, US
Thomas Newsom-Davis - Twickenham, GB
Lawrence Steinman - Stanford CA, US
Gavin Screaton - London, GB
Thomas Newsom-Davis - Twickenham, GB
Lawrence Steinman - Stanford CA, US
Gavin Screaton - London, GB
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Imperial College of London - London
Imperial College of London - London
International Classification:
A61K 39/395, C07H 3/06, C07K 16/30, C07K 16/00, C07K 19/00, A61P 35/00, C12N 9/96, C12N 5/00, G01N 33/53, C40B 40/12, C40B 30/04
US Classification:
4241331, 5361231, 5303875, 5303873, 5303913, 4241371, 435188, 435325, 435 721, 506 19, 506 9
Abstract:
The present invention relates to a novel glycan marker of cancer and monoclonal antibodies against it. Furthermore, novel glycan markers and their use in the detection and monitoring of cancerous cells and cancer-associated or specific antibody signatures are described.
Small Heat Shock Proteins And Active Fragments Thereof As A Therapy For Inflammation And Ischemia
US Patent:
2013007, Mar 21, 2013
Filed:
Jun 22, 2012
Appl. No.:
13/531114
Inventors:
Lawrence Steinman - Stanford CA, US
Jonathan Rothbard - Sonoma CA, US
Jonathan Rothbard - Sonoma CA, US
International Classification:
A61K 38/17, A61K 39/44
US Classification:
4241341, 514 187, 514 44 R, 514 19, 530350, 5303873, 536 235
Abstract:
The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides small heat shock protein activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease.
Methods For Treatment Of Multiple Sclerosis Using Peptide Analogues At Position 91 Of Human Myelin Basic Protein
US Patent:
2004021, Oct 28, 2004
Filed:
Apr 8, 2004
Appl. No.:
10/820983
Inventors:
Lawrence Steinman - Palo Alto CA, US
Nicholas Ling - San Diego CA, US
Paul Conlon - Solana Beach CA, US
Amitabh Gaur - San Diego CA, US
Nicholas Ling - San Diego CA, US
Paul Conlon - Solana Beach CA, US
Amitabh Gaur - San Diego CA, US
International Classification:
A61K038/17, C07K014/47
US Classification:
514/012000, 530/350000
Abstract:
Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.
T-Cell Receptor Varible Transcripts As Disease Related Markers
US Patent:
5667967, Sep 16, 1997
Filed:
May 21, 1993
Appl. No.:
8/066325
Inventors:
Lawrence Steinman - Palo Alto CA
Jorge Oksenberg - Palo Alto CA
Claude Bernard - North Baldwin, AU
Jorge Oksenberg - Palo Alto CA
Claude Bernard - North Baldwin, AU
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
C12P 1934, C12Q 168
US Classification:
435 6
Abstract:
Methods are provided for determining relations between autoimmune degenerative diseases and specific variable regions of T-cell receptors as associated with the host HLA or T-cells associated with umbatting neoprofilerative diseases. By identifying the particular T-cell receptors which cause or are the disease in mammals, various prophylactic and therapeutic techniques may be employed for inhibiting the attack of the T-cell receptors on the native protein or tissue enhance the defense. In addition, individuals may be diagnosed as to their propensity for a particular autoimmune disease or the occurrence of such a disease.
Therapeutic Inhibition Of Granulocyte Function In Demyelinating Disease
US Patent:
2013004, Feb 21, 2013
Filed:
Feb 11, 2011
Appl. No.:
13/577579
Inventors:
Robert C. Axtell - Menlo Park CA, US
Lawrence Steinman - Stanford CA, US
Lawrence Steinman - Stanford CA, US
International Classification:
A61K 31/225, A61P 25/00, A61P 29/00
US Classification:
514548
Abstract:
Compositions and methods are provided for the treatment of IL-17-type inflammatory demyelinating diseases with inhibitors of granulocyte function, e.g. elastase inhibitors. Diseases of interest include multiple sclerosis, neuromyelitis optica, animal models of such diseases, etc. In some embodiments pharmaceutical formulations comprising an elastase inhibitor in an effective dose for treatment of IL-17-type inflammatory demyelinating disease and a pharmaceutically acceptable excipient are provided. Patients may be classified into subtypes prior to treatment, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest.
Dna Vaccination For Treatment Of Autoimmune Disease
US Patent:
7030098, Apr 18, 2006
Filed:
Sep 5, 2001
Appl. No.:
09/947770
Inventors:
Lawrence Steinman - Palo Alto CA, US
Pedro Ruiz - Menlo Park CA, US
Hideki Garren - Stanford CA, US
Pedro Ruiz - Menlo Park CA, US
Hideki Garren - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 31/70
US Classification:
514 44, 4241851
Abstract:
A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-γ and IL-15, are reduced.
Osteopontin Specific Antibodies And Methods Of Use Thereof
US Patent:
2010012, May 27, 2010
Filed:
Aug 24, 2009
Appl. No.:
12/546204
Inventors:
David T. Denhardt - Bridgewater NJ, US
Lawrence Steinman - Stanford CA, US
Lawrence Steinman - Stanford CA, US
International Classification:
A61K 39/395, C07K 16/18, A61P 19/02, A61P 25/28, A61P 37/00, G01N 33/566, G01N 33/53
US Classification:
4241521, 5303882, 436501, 435 71
Abstract:
Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders.